STA
CORT icon

Summit Trail Advisors’s Corcept Therapeutics CORT Stock Holding History

Summit Trail Advisors’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$694K Sell
7,984
-1,676
-17% -$101K 0.01% 1124
2026
Q1 		$389K Buy
+9,660
New +$361K 0.01% 1243
2025
Q4 		– Sell
-3,148
Closed -$262K – 1323
2025
Q3 		$262K Buy
+3,148
New +$228K ﹤0.01% 1235

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Summit Trail Advisors's CORT Position: Q2 2026 in Review

Summit Trail Advisors reduced its Corcept Therapeutics (CORT) stake by 17% in Q2 2026, selling an estimated $101K and leaving 7,984 shares worth $694K. The position accounts for 0.01% of the portfolio, ranked #1124.

Summit Trail Advisors first reported a position in CORT in Q3 2025 and has held it in 3 quarters since. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Summit Trail Advisors held 7,984 shares of Corcept Therapeutics worth $694K as of Q2 2026.
  • Summit Trail Advisors sold 1,676 Corcept Therapeutics shares in Q2 2026, an estimated $101K.
  • Corcept Therapeutics made up 0.01% of Summit Trail Advisors's portfolio in Q2 2026, its #1124 holding.
  • Summit Trail Advisors first reported a position in Corcept Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Summit Trail Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.